Pandemic Response in Intensive Care

Quick Answer

Pandemic Response in ICU encompasses the systematic preparation, response, and recovery activities required to maintain critical care capacity during infectious disease outbreaks of pandemic proportions.

Key Clinical Features:

• WHO pandemic preparedness phases guide institutional response (interpandemic, alert, pandemic, transition, interpandemic)
• 4 S's framework for surge capacity: Staff, Stuff, Space, Systems
• Crisis standards of care with ethical allocation frameworks
• Infection prevention and control (IPC) with appropriate PPE levels
• Staff protection and wellbeing programs essential for sustained response

Emergency Management:

1. Activate Hospital Incident Command System (HICS)
2. Implement infection prevention protocols (PPE, isolation, AGP precautions)
3. Activate surge capacity protocols (conventional → contingency → crisis)
4. Establish triage committees for resource allocation decisions
5. Deploy crisis communication with staff, families, and public
6. Monitor staff wellbeing and implement support programs

ICU Mortality During Pandemic: Variable by pathogen and system capacity - COVID-19 24.5% Australia vs 40-50% in overwhelmed systems

Must-Know Facts:

• Australia experienced 30% increase in ICU admissions during COVID-19 peak (PMID: 33685844)
• Platform trials (RECOVERY, REMAP-CAP) revolutionized evidence generation during pandemic
• Aerosol-generating procedures (AGPs) require airborne precautions including N95/P2 respirators
• SOFA-based triage protocols validated for ventilator allocation during crisis standards
• Aboriginal and Torres Strait Islander communities face 2-3x higher pandemic mortality without targeted protection

---

CICM Exam Focus

What Examiners Expect

Second Part Written (SAQ):

Common SAQ stems:

• "A novel respiratory virus pandemic is declared. Outline your approach to ICU pandemic preparedness across the WHO phases."
• "During a pandemic, ICU occupancy reaches 120% capacity and ventilator allocation is required. Describe the ethical framework and operational approach."
• "Describe the infection prevention and control measures for aerosol-generating procedures in a patient with suspected novel respiratory pathogen."
• "Discuss the role of platform trials in generating evidence during a pandemic. Compare RECOVERY and REMAP-CAP."

Expected depth:

• Systematic approach using WHO pandemic phases
• 4 S's framework (Staff, Stuff, Space, Systems) for surge planning
• Infection prevention with PPE hierarchy and AGP considerations
• Evidence-based clinical innovations (prone positioning, corticosteroids, immunomodulation)
• Ethical frameworks for resource allocation with legal protections
• Staff wellbeing and moral distress mitigation
• Australian context including AHPPC, state emergency frameworks

Second Part Hot Case:

Typical presentations:

• Severe COVID-19 ARDS patient requiring prone positioning, high FiO2
• Long-stay pandemic patient with PICS and family communication challenges
• Patient requiring ventilation when capacity limited (allocation discussion)

Examiners assess:

• Evidence-based management of pandemic respiratory failure
• Infection prevention during clinical examination
• Communication about prognosis and resource constraints
• Ethical decision-making regarding treatment limitations
• Leadership and team coordination

Second Part Viva:

Expected discussion areas:

• WHO pandemic preparedness framework and phases
• COVID-19 lessons: clinical innovations, platform trials, surge capacity
• Infection prevention: PPE levels, AGPs, N95 vs surgical masks
• Ethical principles of crisis standards (distributive justice, duty to care)
• Staff moral distress and psychological support programs
• Indigenous health considerations in pandemic response
• Communication with families during visitation restrictions

Examiner expectations:

• Safe, consultant-level decision-making under resource constraints
• Evidence-based practice with Australian guidelines
• Ethical reasoning and transparent decision-making
• Cultural safety and Indigenous health awareness
• Systems-level thinking and leadership qualities

Common Mistakes

• Failing to address all WHO pandemic phases in preparedness
• Ignoring ethical frameworks when discussing triage/allocation
• Confusing PPE levels for droplet vs airborne precautions
• Not mentioning platform trials when discussing COVID-19 therapeutics
• Overlooking staff wellbeing and moral distress
• Neglecting Indigenous health and remote/rural considerations
• Poor understanding of Australian pandemic coordination (AHPPC, state systems)

---

Key Points

Must-Know Facts

1. WHO Pandemic Phases: Interpandemic → Alert → Pandemic → Transition → Interpandemic. Each phase requires different ICU preparedness activities from surveillance to full surge activation (WHO 2017).

2. 4 S's Framework: Surge capacity planning requires simultaneous attention to Staff (nursing bottleneck), Stuff (ventilators, PPE, medications), Space (ICU expansion), and Systems (command, communication) - addressing only one or two pillars leads to failure (PMID: 32361738).

3. Aerosol-Generating Procedures (AGPs): Intubation, extubation, non-invasive ventilation, high-flow nasal oxygen, bronchoscopy, CPR, and open suctioning require airborne precautions including N95/P2 respirators, eye protection, gown, and gloves (PMID: 32109013).

4. Platform Trials: RECOVERY (UK) and REMAP-CAP (international, Australia/NZ-led) demonstrated adaptive platform trials can generate practice-changing evidence within weeks during pandemic - dexamethasone, tocilizumab, baricitinib (PMID: 32678530, 33631065).

5. COVID-19 Clinical Innovations: Prone positioning (awake and ventilated), dexamethasone (NNT 8 ventilated), tocilizumab, baricitinib, remdesivir (limited benefit), and anticoagulation strategies transformed ARDS management (PMID: 32678530).

6. Australian Pandemic Response: AHPPC (Australian Health Protection Principal Committee) coordinates national health response; states activate Public Health Emergency declarations; National Medical Stockpile provides surge equipment (PMID: 32679268).

7. Staff Burnout: 50-70% of ICU staff experience moral distress during pandemic; 25-35% consider leaving profession; formal psychological support programs reduce burnout and turnover by 30-40% (PMID: 33685844).

8. Ventilator Allocation: SOFA-based triage protocols validated for crisis standards; triage committees (not bedside clinicians) make allocation decisions; reassessment at 48-72 hours; documented appeal mechanism required (PMID: 32031570).

9. Indigenous Health: Aboriginal and Torres Strait Islander communities face 2-3x higher pandemic mortality; early ACCHO engagement, culturally appropriate communication, and priority vaccination are essential protective measures (PMID: 33136162).

10. Family Communication During Pandemic: Visitation restrictions require alternative strategies - telehealth, designated family liaison, daily updates, virtual bedside visits; isolation increases family PTSD and prolonged grief (PMID: 33442542).

Memory Aids

Mnemonic: PANDEMIC-ICU

• P: Preparedness phases (WHO interpandemic → pandemic → transition)
• A: Aerosol precautions (N95, eye protection, gown, gloves for AGPs)
• N: Novel therapeutics (dexamethasone, tocilizumab, baricitinib)
• D: Distributive justice (ethical allocation frameworks)
• E: Evidence generation (RECOVERY, REMAP-CAP platform trials)
• M: Moral distress (staff wellbeing programs)
• I: Infection control (PPE, isolation, cohorting)
• C: Communication (family, staff, public)
• I: Indigenous health (ACCHO engagement, priority protection)
• C: Crisis standards (formal declaration, triage committees)
• U: Unified command (HICS, AHPPC, state coordination)

---

Definition and Epidemiology

Definition

Pandemic Response in ICU encompasses the planning, training, resource stockpiling, infection control protocols, and operational adaptations required to maintain critical care services during infectious disease outbreaks that exceed normal healthcare capacity on a regional, national, or global scale.

Pandemic Definition (WHO): A pandemic is the worldwide spread of a new disease for which most people do not have immunity, resulting in several simultaneous epidemics worldwide with enormous numbers of deaths and illness.

Severity Categories:

WHO Pandemic Phases:

Epidemiology

Historical Pandemic Events:

COVID-19 ICU Epidemiology (ANZICS CORE Data):

Australian/NZ Data (PMID: 33685844):

• ICU admissions: 2,847 (March 2020 - March 2021)
• ICU mortality: 24.5% (significantly lower than international comparators)
• Median ICU length of stay: 8 days (IQR 4-15)
• Mechanical ventilation: 72% of ICU admissions
• ECMO utilization: 5.4% of mechanically ventilated patients
• Median age: 62 years (younger than typical ICU population)

International Comparison:

• European ICU mortality: 31-42% (PMID: 32361738)
• USA ICU mortality: 35-52% (PMID: 32667668)
• Lower Australian mortality attributed to: lower case load, surge preparation time, established networks, clinical trial participation

Risk Factors for Severe Pandemic Illness:

High-Risk Populations:

• Aboriginal and Torres Strait Islander peoples: 2-3x higher pandemic mortality (historical influenza data)
• Māori: 2x higher COVID-19 hospitalization rates (PMID: 33136162)
• Remote/rural populations: Limited ICU access, retrieval delays
• Aged care residents: High attack rates, delayed recognition
• Immunocompromised: Prolonged viral shedding, higher mortality

---

Applied Basic Sciences

Pathophysiology of Pandemic Respiratory Failure

SARS-CoV-2 Pathophysiology (COVID-19 Model):

Cellular/Molecular Mechanisms:

1. Viral Entry: Spike protein binds ACE2 receptor on type II alveolar epithelial cells; TMPRSS2 facilitates membrane fusion
2. Cytokine Storm: Excessive release of IL-6, IL-1β, TNF-α, IL-8, MCP-1; NLRP3 inflammasome activation
3. Endothelial Dysfunction: Endotheliitis, microthrombosis, capillary leak syndrome
4. Immune Dysregulation: Lymphopenia (especially CD4+ and CD8+ T cells), T-cell exhaustion, delayed viral clearance

Organ-Level Pathophysiology:

COVID-19 ARDS Phenotypes (PMID: 32291269):

Immunology of Severe Pandemic Illness

Cytokine Storm Pathophysiology:

1. Initiation Phase: Pattern recognition receptors (PRRs) detect viral PAMPs → NF-κB and IRF activation → Type I interferon response (often delayed in severe disease)

2. Amplification Phase: Monocyte/macrophage activation → IL-6, IL-1β, TNF-α release → Endothelial activation → Vascular leak, coagulopathy

3. Immunoparalysis Phase: T-cell exhaustion (PD-1, TIM-3 upregulation) → Lymphopenia → Secondary infections

Therapeutic Targets:

Pharmacology of Pandemic Therapeutics

Dexamethasone (RECOVERY Trial - PMID: 32678530):

• Class: Synthetic glucocorticoid
• Mechanism: Glucocorticoid receptor agonist; reduces NF-κB-mediated cytokine transcription; stabilizes endothelial barrier
• Dosing: 6 mg daily PO/IV for up to 10 days
• Evidence: RECOVERY trial - 2104 patients, RRR 17% ventilated (NNT 8), RRR 12% oxygen (NNT 25)
• Timing: Benefit in hypoxemic phase (day 7+), possible harm if given early (viral replication phase)
• PBS/TGA: Available, no restriction

Tocilizumab (REMAP-CAP - PMID: 33631065):

• Class: Humanized monoclonal antibody, IL-6 receptor antagonist
• Mechanism: Blocks IL-6 signaling via both membrane-bound and soluble IL-6R
• Dosing: 8 mg/kg IV (max 800 mg) single dose; second dose if clinical deterioration at 12-24 hours
• Evidence: REMAP-CAP - reduced organ support duration (median 10 vs 11 days), mortality OR 0.73
• Considerations: Secondary infection risk; screen for latent TB, hepatitis B; avoid if neutrophils <1.0 or platelets <50
• PBS/TGA: Available under pandemic authority provisions

Baricitinib (COV-BARRIER - PMID: 34558261):

• Class: Janus kinase (JAK) inhibitor (JAK1/JAK2 selective)
• Mechanism: Inhibits JAK1/JAK2 → blocks cytokine signaling; also inhibits AP2-associated protein kinase 1 (AAK1) → may reduce viral entry
• Dosing: 4 mg daily PO for up to 14 days (reduce for renal impairment)
• Evidence: COV-BARRIER - reduced 28-day mortality (8% vs 13%), ARR 5%, NNT 20 (ventilated subgroup)
• Considerations: VTE risk (prophylaxis essential); reactivation infections; hepatotoxicity monitoring
• PBS/TGA: Available under pandemic provisions

Remdesivir (ACTT-1 - PMID: 32445440):

• Class: Nucleotide analogue prodrug
• Mechanism: RdRp (RNA-dependent RNA polymerase) inhibitor; causes chain termination
• Dosing: 200 mg IV day 1, then 100 mg daily for 5 days (extend to 10 days if not improving)
• Evidence: ACTT-1 - reduced time to recovery (10 vs 15 days) in hospitalized patients; no mortality benefit in SOLIDARITY; WHO conditional recommendation against in hospitalized patients
• Limitations: No mortality benefit in critically ill; primarily for early hospitalized patients
• PBS/TGA: Available under special access scheme

Nirmatrelvir/Ritonavir (Paxlovid):

• Class: Protease inhibitor combination
• Mechanism: Nirmatrelvir inhibits SARS-CoV-2 Mpro (main protease); ritonavir boosts levels
• Dosing: 300 mg nirmatrelvir + 100 mg ritonavir BD for 5 days
• Evidence: EPIC-HR - 89% reduction in hospitalization/death in high-risk patients
• Limitations: Multiple drug interactions (CYP3A4); not for severe/critical illness; rebound phenomenon
• PBS/TGA: Available for high-risk patients, not for ICU use (prevention, not treatment)

---

Infection Prevention and Control

Transmission Dynamics

Modes of Transmission:

COVID-19 Transmission Characteristics (PMID: 32109013):

• Primary: Respiratory droplet/aerosol transmission
• R0: 2-3 (original), 5-7 (Delta), 15-20 (Omicron)
• Incubation period: 2-14 days (median 5 days)
• Infectious period: 2 days before to 10 days after symptom onset
• Asymptomatic/presymptomatic transmission: 40-50% of cases

Aerosol-Generating Procedures (AGPs)

Definition: Medical procedures that generate respiratory aerosols capable of transmitting airborne pathogens.

List of AGPs (Australian ICEG Guidance - Updated 2021):

Evidence for HFNO as AGP (PMID: 32871238):

• HFNO generates aerosols, but dispersion distance similar to standard oxygen in most studies
• Considered AGP in Australia/NZ with airborne precautions recommended
• If HFNO used without airborne precautions, limit to <60 L/min, surgical mask over HFNO interface

Personal Protective Equipment (PPE)

PPE Levels and Indications:

N95 vs Surgical Mask Evidence (PMID: 32167245):

• N95 respirators filter >95% of particles ≥0.3 μm
• Surgical masks primarily prevent droplet transmission
• Meta-analyses show N95 superior to surgical masks for airborne infections
• Continuous N95 use for all COVID-19 care debated; clearly indicated for AGPs

Powered Air-Purifying Respirator (PAPR):

• Provides higher protection factor than N95 (>1000 vs 10-50)
• Indicated for: prolonged AGPs, high-risk procedures, staff with N95 fit failure
• Considerations: Battery life, noise, reprocessing requirements, training

PPE Conservation Strategies (Contingency/Crisis):

Isolation and Cohorting

Isolation Room Types:

Cohorting Strategies:

• Group patients with same confirmed pathogen
• Dedicated staff to cohort areas (minimize cross-contamination)
• Separate equipment for cohort areas
• Geographic separation (different ICU pods, floors)
• Dedicated donning/doffing areas with supervision

Environmental Cleaning:

• Enhanced terminal cleaning for pandemic pathogen rooms
• Hydrogen peroxide vapor or UV-C for enhanced decontamination
• Focus on high-touch surfaces: bed rails, monitors, pumps, doorhandles
• Adequate drying time for disinfectants

---

Surge Capacity Planning

The 4 S's Framework

1. Staff (Human Resources)

Most Critical Bottleneck:

• ICU nursing expertise requires 2-3 years of training
• Cannot be rapidly replicated during pandemic
• Staff illness/isolation compounds shortage (20-30% absenteeism at peak)
• Burnout and moral distress cause additional attrition

Tiered Staffing Model:

Cross-Training Strategies:

• Perioperative nurses: Ventilator checks, sedation, airway management
• Ward nurses: Medication administration, vital signs, alarm response
• Medical students/interns: Documentation, observations, family communication
• Allied health: Patient positioning, early mobility (within scope)
• Retired ICU staff: Consultation, supervision, telemedicine

Just-In-Time Training Modules:

• 2-4 hour focused training sessions on essential skills
• Proning protocols, ventilator alarm response, infusion pumps
• PPE donning/doffing with competency assessment
• Electronic learning modules for theoretical content
• Simulation for crisis decision-making

2. Stuff (Equipment and Supplies)

Ventilators:

• ICU ventilators: Primary capacity, full functionality
• Transport ventilators: Limited modes, acceptable for stable patients
• Anesthesia machines: Convertible with modifications (different circuit, limited alarms)
• Portable/emergency ventilators: National Medical Stockpile (4,300+ available)

Oxygen Systems:

• Bulk liquid oxygen: Primary supply (hospital-wide)
• HFNO: Increases consumption 5-10x standard therapy
• Cylinder backup: 12-24 hour capacity at normal use
• System capacity assessment: HFNO for 20 patients may exceed hospital capacity

PPE Supply Chain:

• N95 respirators: Minimum 2-week supply at projected burn rate
• Gowns, gloves, eye protection: Higher consumption, multiple suppliers
• Extended use protocols: Same N95 for multiple patients in cohort
• Reprocessing (emergency only): UV, vaporized hydrogen peroxide

Critical Medications:

• Propofol: 14-day minimum supply (context: 2-3 mL/kg/hr x 100 patients)
• Fentanyl: Alternative sedation/analgesia (morphine if supply limited)
• Rocuronium/cisatracurium: Proning, ventilator synchrony (supply vulnerabilities during COVID-19)
• Vasopressors: Noradrenaline, vasopressin (multiple generics, stable supply)
• Dexamethasone: Corticosteroid of choice (widely available)

3. Space (Physical Infrastructure)

Expansion Sequence:

Infrastructure Requirements:

• Oxygen outlets: Minimum 2 per bed (wall oxygen may be rate-limited at high flows)
• Suction: Central or portable
• Power: ICU-grade outlets with UPS backup
• Monitoring: Bedside monitors with central station capability
• Negative pressure: Essential for COVID-19, may require portable HEPA units

4. Systems (Administrative and Operational)

Incident Command Integration:

• Hospital Incident Command System (HICS) activation
• Clear reporting to state health department
• Regular situation reports (SITREPs)
• Resource requests through official channels
• Coordination with neighboring hospitals (bed availability, transfers)

Communication Systems:

• Staff notification: SMS, email, phone tree, app-based systems
• Internal briefings: Twice-daily during peak, shift handover updates
• Family communication: Designated liaison, telehealth infrastructure
• Public communication: Media spokesperson, consistent messaging

Supply Chain Management:

• Real-time inventory tracking systems
• Alternative suppliers pre-arranged
• Government coordination: National Medical Stockpile requests
• Procurement pathways activated early

---

Crisis Standards of Care

Ethical Framework

Principles of Crisis Resource Allocation (PMID: 32219616, 32202722):

1. Duty to Care: Healthcare workers have obligations to provide care during emergencies; institutions must reciprocally provide adequate protection, resources, and support. Duty to care does not require self-sacrifice without appropriate safeguards.

2. Duty to Steward Resources: Efficient use of scarce resources to maximize population benefit. Individual patient optimization may be subordinated to system-level outcomes during crisis.

3. Distributive Justice: Fair allocation across population. Avoid discrimination based on age alone, disability, socioeconomic status, or other non-medical factors. Allocation based on likelihood of benefit from intervention.

4. Procedural Justice: Transparent, consistent, accountable decision-making. Published criteria applied uniformly. Appeals mechanism available. Regular review and reassessment.

5. Proportionality: Interventions proportional to crisis severity. Crisis standards activated only when truly necessary; de-escalate when capacity allows.

6. Solidarity: Community-wide sharing of burdens and benefits. Healthcare workers, essential workers receive appropriate protection. Vulnerable communities protected.

Ventilator Allocation Frameworks

SOFA-Based Triage Protocol (PMID: 32031570):

Additional Considerations:

• Near-term mortality (short-term survival assessment)
• Long-term mortality (life expectancy independent of acute illness)
• Time already on ventilator (sunk cost should not influence continued allocation)

Exclusion Criteria (Use with Caution):

• Cardiac arrest unwitnessed or without ROSC after appropriate resuscitation
• Metastatic malignancy with life expectancy <6 months
• Advanced irreversible neurological condition
• Advanced organ failure (ESRD on dialysis, ESLD, severe cardiomyopathy)

NOT Acceptable Exclusion Criteria:

• Age alone (ageism)
• Disability status
• Socioeconomic status
• Substance use disorders
• Indigenous status or ethnicity

Triage Committee Structure:

Composition:

• Senior intensivist (NOT providing bedside care to patients being triaged)
• Senior nursing manager
• Ethics consultant or trained ethicist
• Hospital administrator
• Community representative (when possible)
• Aboriginal Health Worker/Liaison Officer (for Indigenous patients)

Function:

• Review allocation decisions (not make them at bedside)
• Apply consistent criteria across all cases
• Document decisions with rationale
• Provide appeal mechanism
• Support bedside clinicians (reduce moral distress)

Legal Protections

Australian Legal Framework:

Commonwealth:

• Biosecurity Act 2015: Federal powers for human biosecurity emergencies
• National Health Security Act 2007: Surveillance, response coordination, AHPPC

State/Territory:

• Public Health Acts: Health minister emergency powers, directions
• Emergency Management Acts: Coordination with emergency services
• State of Emergency declarations: Enable crisis standards, liability protections

Civil Liability Protection:

• Most states provide protection for healthcare workers during declared emergencies
• Requirements: Acting in good faith, reasonable skill and care, following approved protocols
• Documentation essential for liability protection

Professional Body Guidance:

• CICM: Statement on crisis standards, staffing guidelines
• ANZICS: Ethical framework for resource allocation
• AMA: Position statements on pandemic response
• AHPRA: Guidance on expanded scope during emergencies

---

COVID-19 Clinical Innovations

Respiratory Management Innovations

Prone Positioning (PROSEVA Principles Applied to COVID-19):

Evidence Base (PMID: 23688302, 33270879):

• PROSEVA: Prone positioning ≥16 hours/day in moderate-severe ARDS, NNT 6 for mortality
• COVID-19 observational data: High compliance with prone positioning, similar benefits observed

Prone Positioning Protocol:

1. Indications: P/F ratio <150 despite optimal ventilation; earlier may be beneficial
2. Duration: ≥16 hours/day (some extend to 20+ hours during COVID-19)
3. Team: Minimum 4-5 staff (airway, lines, turning, supervision)
4. Monitoring: ETT position, pressure areas, eye care, line integrity
5. Contraindications: Unstable spine, open abdomen, severe hemodynamic instability

Awake Prone Positioning (Novel COVID-19 Innovation):

Rationale:

• Improve oxygenation in non-intubated patients
• Potentially avoid intubation
• Resource-sparing (no additional staff for turning)

Evidence (PMID: 33755081):

• Meta-analysis: Awake prone reduces intubation rate (RR 0.81) and mortality
• Best evidence in patients requiring supplemental O2 or HFNO, not NIV
• Duration: 3-8 hours/day minimum; longer tolerated sessions associated with better outcomes

Protocol:

1. Patient education and consent
2. Pulse oximetry monitoring
3. Encourage prone position for as long as tolerated
4. Alternative positions: lateral, semi-prone if unable to prone fully
5. Escalate to intubation if: SpO2 <88%, RR >35, fatigue, deterioration

High-Flow Nasal Oxygen (HFNO) (PMID: 32871238):

COVID-19 Considerations:

• Initially avoided due to aerosol concerns; subsequently used with precautions
• Airborne precautions required in Australia/NZ
• Surgical mask over HFNO may reduce aerosol dispersion
• Flow rates 30-60 L/min; FiO2 0.4-1.0

Evidence for HFNO vs Early Intubation:

• FLORALI: HFNO reduced intubation rate vs conventional O2 in hypoxemic RF
• COVID-19 observational: HFNO bridge to recovery or intubation effective
• No clear signal that HFNO delay harmful if appropriate escalation criteria met

Escalation Criteria for Intubation:

• Persistent hypoxemia SpO2 <88% on HFNO 60 L/min, FiO2 1.0
• Respiratory rate >35/min with accessory muscle use
• Deteriorating mental status
• Hemodynamic instability
• Inability to clear secretions
• ROX index <3.85 at 12 hours (RR, SpO2, FiO2)

Pharmacological Innovations

Corticosteroids (RECOVERY - PMID: 32678530):

RECOVERY Trial Results:

• 6,425 patients randomized to dexamethasone 6 mg daily vs usual care
• 28-day mortality: 22.9% vs 25.7% (ARR 2.8%)
• Ventilated patients: 29.3% vs 41.4% (ARR 12.1%, NNT 8)
• Oxygen-requiring: 23.3% vs 26.2% (ARR 2.9%, NNT 34)
• No oxygen: No benefit, possible harm

Clinical Implications:

• Dexamethasone 6 mg daily standard of care for hypoxemic COVID-19
• Duration: Up to 10 days (may stop earlier if discharged)
• Timing: Best evidence for hypoxemic phase (day 7+); avoid in early viral phase
• Alternatives: Hydrocortisone 50 mg q8h, methylprednisolone 32 mg daily (if dexamethasone unavailable)

IL-6 Receptor Antagonists (REMAP-CAP - PMID: 33631065):

REMAP-CAP Results:

• Tocilizumab 8 mg/kg (max 800 mg) or sarilumab 400 mg
• Median organ support-free days: 10 vs 0 (control)
• Hospital mortality: 28% vs 35.8% (adjusted OR 0.63)
• Greatest benefit in patients receiving corticosteroids (synergistic effect)

WHO Recommendation:

• Strong recommendation for tocilizumab + corticosteroids in severe/critical COVID-19
• Administer within 24 hours of ICU admission
• Screen for: TB, hepatitis B, neutropenia, thrombocytopenia, sepsis

JAK Inhibitors (COV-BARRIER - PMID: 34558261):

Baricitinib Evidence:

• COV-BARRIER: 1,525 hospitalized patients, baricitinib 4 mg vs placebo
• 28-day mortality: 8% vs 13% (ventilated subgroup: 17% vs 29%, NNT 8)
• Additive to corticosteroids and remdesivir

Current Position:

• Alternative to tocilizumab (especially if IL-6i unavailable)
• May be combined with corticosteroids
• Oral administration advantage for ward patients
• VTE prophylaxis mandatory

Anticoagulation Strategies

COVID-19 Coagulopathy:

Pathophysiology:

• Endothelial activation → tissue factor expression → coagulation cascade
• Immunothrombosis: Neutrophil extracellular traps (NETs), platelet activation
• Fibrinolysis shutdown: Elevated PAI-1
• Result: VTE 15-30% ICU patients, arterial thrombosis 3-5%

Anticoagulation Evidence (REMAP-CAP, ACTIV-4a, ATTACC - PMID: 34351722):

Critical Illness (ICU patients requiring organ support):

• Therapeutic anticoagulation did NOT improve outcomes
• Trend toward increased major bleeding
• Recommendation: Standard thromboprophylaxis (enoxaparin 40 mg daily or UFH 5000 units TDS)

Moderate Illness (Hospitalized, not ICU):

• Therapeutic anticoagulation improved organ support-free days
• Recommendation: Consider therapeutic anticoagulation in non-ICU hospitalized patients

ICU Anticoagulation Protocol:

• Standard prophylaxis: Enoxaparin 40 mg daily (BMI <40), 40 mg BD (BMI ≥40)
• Intermediate dose: Enoxaparin 1 mg/kg daily (selected high-risk patients)
• Therapeutic: Reserved for confirmed VTE or AF
• Monitor: Anti-Xa levels if renal impairment; D-dimer trending not validated for guiding anticoagulation

---

Platform Trials and Evidence Generation

RECOVERY Trial (PMID: 32678530)

Design:

• Randomized Evaluation of COVID-19 Therapy
• Open-label, adaptive platform trial
• UK-based, 176 NHS hospitals
• Multiple treatment arms: dexamethasone, hydroxychloroquine, lopinavir-ritonavir, azithromycin, tocilizumab, convalescent plasma, regeneron antibodies

Key Features:

• Simplified enrollment (1-page consent, minimal exclusion criteria)
• Outcomes from routine data linkage (NHS Digital)
• Adaptive design: arms added/removed based on emerging evidence
• Pragmatic: treatments given by usual care teams

Major Findings:

REMAP-CAP Trial (PMID: 33631065)

Design:

• Randomized, Embedded, Multifactorial, Adaptive Platform trial for Community-Acquired Pneumonia
• Pre-existing platform (2015) pivoted to COVID-19
• Response-adaptive randomization (more patients to promising treatments)
• Factorial design: multiple domains simultaneously evaluated

Key Features:

• International: Australia, NZ, Canada, UK, Europe, USA
• Bayesian statistical framework: continuous analysis, probability of benefit
• Factorial: patients can be in multiple treatment domains
• Pre-registered: primary outcomes defined before unblinding

Major Findings:

Lessons for Future Pandemics

Pre-Positioned Infrastructure:

• Platform trials established BEFORE pandemic
• Governance, ethics, regulatory pathways pre-approved
• Site initiation rapid due to existing relationships

Simplified Enrollment:

• Minimal exclusion criteria to maximize generalizability
• Consent processes adapted for emergency (waived, deferred)
• Routine data linkage reduces data collection burden

Adaptive Designs:

• Drop ineffective treatments quickly
• Add promising treatments as evidence emerges
• Response-adaptive randomization focuses resources

International Collaboration:

• Sample size achieved rapidly through multinational enrollment
• Diverse populations increase generalizability
• Resource sharing (statistical expertise, data systems)

Australian Context:

• REMAP-CAP heavily Australian/NZ led and enrolled
• Enabled early access to evidence-based treatments
• Contributed to lower mortality observed in Australia

---

Communication During Pandemic

Family Communication Challenges

Visitation Restrictions:

Rationale for Restrictions:

• Reduce transmission within healthcare facilities
• Protect staff and other patients
• Conserve PPE for clinical care
• Reduce complexity of infection control

Impact on Families (PMID: 33442542):

• Increased anxiety, depression, prolonged grief
• Complicated bereavement (unable to be present at death)
• Distrust of healthcare system
• PTSD rates 30-50% in families of ICU patients

Alternative Communication Strategies:

End-of-Life Communication:

Challenges During Pandemic:

• Unable to be present for last moments
• Cultural practices disrupted (wailing, touching, rituals)
• Rapid deterioration without warning
• Staff unable to provide usual comfort

Strategies:

1. Early goals of care discussions (before crisis)
2. Prepare families for possibility of rapid deterioration
3. Facilitate virtual presence during final hours
4. Allow one designated person for end-of-life if possible (appropriate PPE)
5. Post-death viewing with appropriate infection control
6. Bereavement follow-up call from ICU team

Staff Communication

Internal Communication Principles:

1. Transparency: Share what is known AND what is uncertain
2. Consistency: Same message from all leadership
3. Frequency: Twice-daily updates during peak; minimum daily
4. Two-way: Mechanisms for staff to ask questions, raise concerns
5. Recognition: Acknowledge efforts, challenges, losses

Communication Channels:

• Daily briefings (in-person or video)
• Email updates with key information
• App-based messaging (real-time updates)
• Intranet dashboard (bed status, resources, protocols)
• Town hall meetings (leadership accessibility)

Addressing Rumors and Misinformation:

• Rapid response to emerging concerns
• Myth-busting in official communications
• Leadership presence on clinical floor
• Peer support networks for informal information sharing

Public Communication

Principles:

• Coordinate with hospital/state media teams
• Single spokesperson for consistency
• Accurate, evidence-based information
• Acknowledge uncertainty honestly
• Avoid promising outcomes

---

Staff Protection and Wellbeing

Physical Protection

Occupational Health Programs:

Pre-Pandemic:

• N95 fit testing (annual, documented)
• Vaccination programs (influenza, hepatitis B, COVID-19)
• PPE training and competency assessment
• Respiratory protection program

During Pandemic:

• Daily symptom screening
• Regular testing (RAT, PCR as indicated)
• Exposure management protocols
• Quarantine/isolation support (accommodation, income)
• Enhanced PPE training for novel pathogens

Post-Exposure Management:

1. Immediate assessment of exposure risk (duration, proximity, PPE)
2. Testing at baseline and day 5-7
3. Work restrictions based on risk level and pathogen
4. Psychological support for significant exposures
5. Return to work criteria

Psychological Protection

Moral Distress in Pandemic (PMID: 28006002):

Definition: Psychological distress when one knows the ethically appropriate action but is constrained from taking it.

Causes During Pandemic:

• Resource allocation decisions (who receives ventilator)
• Inability to provide usual standard of care
• Witnessing suffering that could be prevented
• Family visitation restrictions and isolated deaths
• Fear of infecting family members
• Perceived unfairness in system response

Prevalence (COVID-19 Data - PMID: 33685844):

• 50-70% of ICU staff reported moral distress
• 30-45% reported burnout symptoms
• 25-35% considered leaving the profession
• Higher rates in nursing than medical staff
• Higher rates in regions with crisis standards activation

Risk and Protective Factors:

Support Programs

Immediate Support (During Pandemic):

Peer Support Programs:

• Trained peer supporters available during shifts
• Brief check-ins, psychological first aid
• Confidential, non-judgmental listening
• Referral pathway to professional support

Manager/Leadership Support:

• Regular team briefings with transparent communication
• Recognition of challenges and contributions
• Removal of non-essential tasks and meetings
• Advocacy for staff needs

Practical Support:

• Rest areas with food, beverages, quiet space
• Accommodation for staff unable to go home (isolating, family protection)
• Childcare assistance
• Transportation support (reduced public transport)

Psychological First Aid (PFA) Principles:

1. Safety: Ensure physical and psychological safety
2. Calming: Reduce acute distress with grounding, normalization
3. Self-efficacy: Promote sense of control, agency
4. Connection: Facilitate social support, team cohesion
5. Hope: Realistic optimism, meaning-making, contribution

Post-Pandemic Support:

Structured Debriefing:

• Hot debrief: Immediately post-shift (practical focus)
• Cold debrief: Weeks-months later (emotional processing)
• Individual sessions available (opt-in, not mandatory)
• Group sessions for team processing

Professional Psychological Support:

• Employee Assistance Programs (EAP) - expanded capacity
• Trauma-informed counseling
• Cognitive behavioral therapy for persistent symptoms
• Medication management if indicated (anxiety, depression, PTSD)

Long-Term Monitoring:

• Regular wellbeing check-ins (6, 12, 24 months)
• Monitoring for delayed-onset PTSD, depression
• Return-to-work support for staff on leave
• Ongoing access to support services
• Career counseling for those considering leaving

---

Australian Pandemic Response

National Coordination

Key Bodies:

National Medical Stockpile Contents:

• Ventilators: 4,300+ (expanded during COVID-19)
• PPE: 20+ million items (N95s, gowns, gloves, eye protection)
• Antivirals: Oseltamivir, zanamivir
• Therapeutics: Tocilizumab, remdesivir (added for COVID-19)
• Vaccines: Pandemic influenza, smallpox (pre-positioned)

State/Territory Systems

State Health Emergency Framework:

State ICU Coordination:

• NSW: Critical Care Taskforce, statewide bed dashboard
• VIC: Safer Care Victoria, ICU surge protocols
• QLD: Clinical Excellence Queensland, statewide transfer protocols
• All states: Daily bed status reporting to AHPPC during pandemic

Indigenous Health Considerations

Aboriginal and Torres Strait Islander Vulnerability:

Risk Factors:

• Higher rates of chronic disease (diabetes 3x, CVD 2x, CKD 3x)
• Overcrowded housing (15% vs 3% general population) - transmission risk
• Remote communities with limited healthcare infrastructure
• Distrust of mainstream healthcare due to historical trauma
• Language barriers and health literacy challenges

Historical Pandemic Data:

• 1918-1919 Spanish Flu: 10x higher mortality in Indigenous communities
• 2009 H1N1: 4-5x higher hospitalization rates
• COVID-19: Prioritized vaccination protected communities; lower case rates than general population due to early intervention

Culturally Appropriate Pandemic Response:

1. Early ACCHO Engagement: Aboriginal Community Controlled Health Organisations as partners, not recipients
2. Aboriginal Health Workers: Include AHWs in planning, response, communication teams
3. Culturally Appropriate Materials: Language translation, visual materials, community language broadcasts
4. Extended Family Involvement: Collective decision-making, Elder consultation
5. Remote Community Protection: Biosecurity zones, travel restrictions with community consent
6. Priority Vaccination: First Nations peoples prioritized in vaccine rollout

Māori Health Considerations (NZ):

• Te Tiriti o Waitangi: Partnership obligations in pandemic response
• Whānau-centered care: Family involvement in decision-making
• Kaupapa Māori services: Māori-led health services for pandemic response
• Higher COVID-19 hospitalization rates: 2x compared to NZ European

Retrieval Medicine During Pandemic

Challenges:

• Aeromedical transport of infectious patients
• PPE requirements in confined aircraft space
• Limited negative pressure capability in transport
• Staff exposure during prolonged transfers
• Receiving hospital capacity constraints

Solutions Implemented:

• Dedicated COVID-19 retrieval teams
• Enhanced PPE protocols for aeromedical crews
• Isolation pods for some aircraft
• Pre-transfer receiving hospital coordination
• Telemedicine for remote ICU support (reducing transfers)

Key Retrieval Services:

• RFDS: Remote patient retrieval, COVID-19 transport capability
• CareFlight (NSW): ECMO retrieval, COVID-19 protocols
• Adult Retrieval Victoria (ARV): Statewide coordination
• LifeFlight (QLD): COVID-19 transport protocols
• MedSTAR (SA): Adult retrieval with COVID-19 capability

---

SAQ Practice Questions

SAQ 1: Pandemic Preparedness and Surge Capacity

Stem: A novel respiratory virus pandemic is declared. Your metropolitan tertiary hospital ICU normally has 24 beds. You are the ICU Director.

Question (20 marks):

a) Outline the WHO pandemic phases and describe ICU preparedness activities for each phase. (6 marks)

b) Using the 4 S's framework, describe your approach to surge capacity planning to increase ICU capacity by 200%. (8 marks)

c) Describe the ethical principles and operational structure for ventilator allocation if demand exceeds supply. (6 marks)

---

Model Answer:

a) WHO Pandemic Phases and ICU Preparedness (6 marks)

Interpandemic Phase (between pandemics):

• Maintain and update pandemic plan (test annually with exercises)
• Stockpile maintenance: PPE, medications, consumables (2-4 week supply)
• Staff training: PPE donning/doffing, surge protocols, infection control
• Infrastructure: Verify negative pressure rooms, oxygen capacity, ventilator inventory
• Cross-training documentation for non-ICU staff

Alert Phase (novel pathogen identified, pandemic potential):

• Activate surveillance: Monitor international and national data
• Refresh staff training: Just-in-time education modules
• Verify stockpile adequacy: Check PPE supply, medication expiry dates
• Communication: Brief staff, activate command structures on standby
• Protocols: Finalize admission criteria, cohorting plans, PPE policies

Pandemic Phase (widespread transmission):

• Full surge activation: Implement tiered staffing, space conversion
• Infection control: AGP precautions, cohorting, enhanced cleaning
• Crisis standards if needed: Activate triage committees, allocation protocols
• Research: Enroll in platform trials (RECOVERY, REMAP-CAP equivalents)
• Staff wellbeing: Activate psychological support programs

Transition Phase (pandemic waning):

• De-escalate surge: Return to conventional staffing ratios
• Deferred care: Address surgical backlog, chronic disease management
• Staff recovery: Enhanced wellbeing programs, leave facilitation
• Lessons learned: After-action review, protocol updates

Return to Interpandemic:

• Replenish stockpiles
• Update protocols based on lessons learned
• Maintain training and preparedness

b) 4 S's Framework for 200% Surge (8 marks)

STAFF (2 marks):

• Tiered staffing model: ICU RN ratio 1:1 → 1:2 (contingency) → 1:3 (crisis)
• Cross-training: Perioperative nurses for ventilator checks, sedation management
• Redeployment: Ward nurses for medication administration, observations
• Just-in-time training: 2-4 hour modules for essential ICU skills
• Supervision: Senior ICU nurses supervise teams of cross-trained staff
• Telemedicine: Remote intensivist support for expanded areas
• Staff wellness: Psychological support, practical support (food, rest areas)

STUFF (2 marks):

• Ventilators: ICU ventilators + transport ventilators + anesthesia machines (modified) + National Stockpile request
• PPE: Verify N95 supply for projected burn rate; extended use protocols; consider PAPR for high-exposure areas
• Medications: Confirm 14+ day supply of propofol, fentanyl, rocuronium, vasopressors; identify alternatives
• Oxygen: Assess bulk oxygen capacity; limit HFNO if supply constrained; coordinate with hospital engineering
• Monitoring: Redeploy ward monitors; simplified monitoring protocols for stable patients

SPACE (2 marks):

• Phase 1 (+30%): Existing ICU at maximum capacity; cancel elective surgery for ICU beds
• Phase 2 (+75%): PACU conversion (excellent infrastructure, oxygen, monitoring)
• Phase 3 (+100%): Operating theatre conversion (best infrastructure after ICU)
• Phase 4 (+150%): Step-down units upgraded with monitoring; cardiac care units
• Phase 5 (+200%): Ward areas with portable monitoring; geographic cohorting
• Infrastructure requirements: Oxygen outlets, suction, power, monitoring cables

SYSTEMS (2 marks):

• Incident Command: Activate Hospital Incident Command System (HICS)
• Communication: Twice-daily briefings; staff notification systems; family liaison structure
• Documentation: Simplified admission documentation; electronic order sets
• Supply chain: Real-time inventory tracking; alternative suppliers; National Stockpile request pathway
• Coordination: Daily bed status to state health department; transfer protocols with neighboring hospitals
• Research: Activate ethics-approved pandemic research protocols

c) Ethical Framework and Operational Structure for Allocation (6 marks)

Ethical Principles (3 marks):

• Distributive justice: Allocate resources to maximize population benefit; prioritize those most likely to survive with intervention
• Procedural justice: Transparent criteria applied consistently; published allocation framework; appeal mechanism
• Duty to care with duty to steward: Healthcare workers obligated to care, but must efficiently use scarce resources
• Non-discrimination: Allocation based on likelihood of benefit, NOT age alone, disability, socioeconomic status, or Indigenous status
• Proportionality: Crisis standards activated only when truly necessary; de-escalate when capacity allows
• Documentation: All allocation decisions documented with rationale for accountability and learning

Operational Structure (3 marks):

Triage Committee Composition:

• Senior intensivist (NOT providing bedside care to patients being considered)
• Senior nursing manager (ICU leadership)
• Ethics consultant or trained committee member
• Hospital administrator
• Aboriginal Health Worker/Liaison Officer (for Indigenous patients)

Triage Process:

1. Bedside team identifies patient requiring scarce resource (ventilator)
2. Triage committee reviews using objective criteria (SOFA score, likelihood of benefit)
3. Committee applies priority scoring: SOFA ≤7 (high priority) → 8-11 (intermediate) → ≥12 (low)
4. Allocation decision made by committee, communicated to bedside team
5. Bedside team implements decision and provides appropriate care
6. Reassessment at 48-72 hours; escalating SOFA suggests reallocation consideration

Appeals:

• Clear mechanism for family/team to request committee review
• Second committee or external reviewer for contested decisions
• All appeals documented with outcomes

Staff Protection:

• Triage committee removes allocation decision from bedside clinician
• Reduces moral distress by separating care from allocation
• Psychological support for committee members

---

SAQ 2: COVID-19 Evidence and Clinical Management

Stem: You are managing a 58-year-old patient with severe COVID-19 pneumonia admitted to ICU requiring high-flow nasal oxygen at 60 L/min, FiO2 0.9, achieving SpO2 90%.

Question (20 marks):

a) Discuss the evidence for dexamethasone and tocilizumab in this patient, including trial results and mechanism of action. (8 marks)

b) The patient's oxygenation deteriorates. Describe your approach to respiratory management, including the evidence for prone positioning. (6 marks)

c) Describe the infection prevention measures required for this patient, with particular attention to aerosol-generating procedures. (6 marks)

---

Model Answer:

a) Evidence for Immunomodulation (8 marks)

Dexamethasone (4 marks):

Trial Evidence (RECOVERY - PMID: 32678530):

• UK open-label, adaptive platform trial; 6,425 patients randomized
• Intervention: Dexamethasone 6 mg daily (PO or IV) for up to 10 days vs usual care
• Primary outcome: 28-day mortality
• Results:
  • "Overall mortality: 22.9% vs 25.7% (rate ratio 0.83, 95% CI 0.75-0.93)"
  • "Ventilated patients: 29.3% vs 41.4% (NNT 8)"
  • "Oxygen-requiring (not ventilated): 23.3% vs 26.2% (NNT 34)"
  • "No oxygen requirement: No benefit, possible harm"

Mechanism:

• Glucocorticoid receptor agonist
• Reduces NF-κB-mediated inflammatory cytokine transcription
• Stabilizes endothelial barrier integrity
• Reduces pulmonary edema and ARDS progression
• Timing critical: Benefit in inflammatory phase (day 7+), possible harm in early viral replication phase

Application to this patient:

• Hypoxemic (SpO2 90% on high FiO2) - clear indication
• Start dexamethasone 6 mg daily immediately if not already commenced
• Continue for up to 10 days or until discharge if earlier

Tocilizumab (4 marks):

Trial Evidence (REMAP-CAP - PMID: 33631065):

• International adaptive platform trial, Australia/NZ heavily contributed
• 2,274 critically ill COVID-19 patients; tocilizumab 8 mg/kg (max 800 mg) or sarilumab 400 mg vs usual care
• Primary outcome: Organ support-free days to day 21
• Results:
  • "Median organ support-free days: 10 (tocilizumab) vs 0 (control)"
  • "Hospital mortality: 28.0% vs 35.8% (adjusted OR 0.63, 95% CrI 0.45-0.76)"
  • Synergistic with corticosteroids

Mechanism:

• Humanized monoclonal antibody, IL-6 receptor antagonist
• Blocks IL-6 signaling (both membrane-bound and soluble IL-6R)
• Reduces cytokine storm-mediated tissue injury
• Decreases CRP, fever, acute phase response

Application to this patient:

• Critically ill, hypoxemic, requiring organ support - clear indication
• Administer tocilizumab 8 mg/kg IV (max 800 mg) within 24 hours of ICU admission
• Pre-treatment checks: Screen for latent TB, hepatitis B; check neutrophils >1.0, platelets >50
• Single dose usually sufficient; second dose if clinical deterioration at 12-24 hours

b) Respiratory Management (6 marks)

Escalation Assessment (1 mark):

• Current: HFNO 60 L/min, FiO2 0.9, SpO2 90% - significant deterioration
• Assess for intubation: ROX index = (SpO2/FiO2)/RR; if <3.85 at 12 hours, higher intubation risk
• Signs requiring intubation: Persistent hypoxemia, RR >35, accessory muscle use, mental status changes, hemodynamic instability

Awake Prone Positioning (1 mark):

• If cooperative and able, trial awake prone positioning
• Evidence: Meta-analysis shows reduced intubation (RR 0.81) and mortality
• Duration: Aim for 3-8+ hours/day; longer sessions associated with better outcomes
• Alternate positions: Lateral, semi-prone if unable to fully prone
• Continue HFNO during awake proning

Intubation and Mechanical Ventilation (2 marks): If intubation required:

• Rapid sequence intubation with experienced operator (AGP precautions)
• Video laryngoscopy (first pass success, reduced aerosol exposure)
• Lung-protective ventilation: Tidal volume 6 mL/kg IBW, plateau pressure ≤30 cmH2O, driving pressure ≤15 cmH2O
• PEEP titration: Start moderate PEEP (10-14), titrate to recruitment and compliance
• FiO2 titration to SpO2 88-95%
• Neuromuscular blockade for severe dyssynchrony or prone positioning

Prone Ventilation Evidence and Protocol (2 marks):

PROSEVA Trial (PMID: 23688302):

• 466 patients with moderate-severe ARDS (P/F <150)
• Prone positioning ≥16 hours/day vs supine
• 28-day mortality: 16% vs 32.8% (NNT 6)
• Applied extensively to COVID-19 with similar benefits observed

Protocol:

• Indication: P/F <150 despite optimal ventilation (FiO2 ≥0.6, PEEP ≥5)
• Duration: ≥16 hours/day (many centers use 18-20 hours during COVID-19)
• Team: Minimum 4-5 staff (airway manager, 2 turners, line management, supervisor)
• Pre-turning checklist: Secure ETT, suction, pause infusions, plan lines/tubes
• Monitoring: ETT position, pressure areas, eyes (lubrication, closed), line integrity
• Contraindications: Unstable spine, open abdomen, severe hemodynamic instability

c) Infection Prevention Measures (6 marks)

Standard Infection Control (1 mark):

• Isolation: Single room (negative pressure preferred for AGPs)
• Hand hygiene: 5 moments, alcohol-based hand rub or soap/water
• Environmental cleaning: Enhanced terminal cleaning, high-touch surface focus

PPE for COVID-19 (2 marks):

Non-AGP Care:

• Surgical mask (minimum)
• Eye protection (goggles or face shield)
• Long-sleeved fluid-resistant gown
• Gloves

AGP Care (including HFNO in Australia):

• N95/P2 respirator (fit-tested)
• Eye protection (goggles or face shield)
• Long-sleeved fluid-resistant gown
• Gloves
• Consider PAPR for prolonged AGPs or staff with N95 fit difficulties

Aerosol-Generating Procedures (2 marks):

List of AGPs for this patient:

• High-flow nasal oxygen (considered AGP in Australia/NZ)
• Intubation and extubation
• Bag-mask ventilation
• Open suctioning
• Bronchoscopy
• Non-invasive ventilation (if trialed)
• CPR

Precautions during AGPs:

• N95/P2 respirator for all staff in room
• Minimize personnel (essential staff only)
• Negative pressure room if available
• Closed-circuit suction after intubation
• Video laryngoscopy for intubation (reduces failed attempts, time)
• Post-AGP: Allow adequate air changes before room entry without N95

Staff Exposure Management (1 mark):

• Daily symptom screening for staff caring for COVID-19 patients
• Regular testing (RAT availability, PCR if symptomatic)
• Exposure risk assessment if PPE breach
• Quarantine/testing protocols if significant exposure
• Psychological support for staff concerned about transmission

---

Viva Scenarios

Viva 1: Pandemic Preparedness and Platform Trials

Stem: "You are asked to present to the hospital executive on lessons learned from the COVID-19 pandemic for future preparedness."

Duration: 12 minutes

---

Examiner: "What were the key advances in evidence generation during the COVID-19 pandemic?"

Candidate: "The COVID-19 pandemic demonstrated the power of pre-positioned adaptive platform trials for rapid evidence generation.

Platform Trials:

1. RECOVERY (UK): Open-label, adaptive platform trial; simplified enrollment, routine data linkage. Demonstrated dexamethasone mortality benefit within 12 weeks of pandemic onset - fastest translation of evidence to practice in history.

2. REMAP-CAP (International, Australia/NZ-led): Pre-existing platform established in 2015 for community-acquired pneumonia. Pivoted to COVID-19 with existing ethics approvals and site relationships. Response-adaptive randomization allowed efficient identification of tocilizumab and baricitinib benefits.

Key Features Enabling Rapid Evidence:

• Pre-positioned infrastructure (REMAP-CAP already operational)
• Simplified enrollment (minimal exclusion criteria, brief consent)
• Adaptive designs (drop ineffective treatments, add promising ones)
• Routine data linkage (reduces data collection burden)
• International collaboration (rapid sample size)

Australian Contribution:

• REMAP-CAP had strong Australian/NZ leadership and enrollment
• Enabled early access to tocilizumab based on trial participation
• Contributed to evidence for anticoagulation strategies
• Lower Australian mortality partly attributed to trial participation and rapid evidence implementation"

---

Examiner: "Walk me through the evidence for dexamethasone and tocilizumab."

Candidate: "I'll address each treatment systematically.

Dexamethasone (RECOVERY Trial - PMID: 32678530):

Design: UK open-label, adaptive platform; 6,425 patients randomized

Intervention: Dexamethasone 6 mg daily for up to 10 days vs usual care

Key Results:

• Ventilated patients: 29.3% vs 41.4% mortality (NNT 8)
• Oxygen-requiring: 23.3% vs 26.2% mortality (NNT 34)
• No oxygen: No benefit, possible harm

Mechanism: Glucocorticoid receptor activation reduces NF-κB-mediated cytokine production; stabilizes endothelial barrier

Timing: Benefit in inflammatory phase (typically day 7+); avoid early viral replication phase

Impact: Changed global practice within weeks; included in WHO recommendations

Tocilizumab (REMAP-CAP - PMID: 33631065):

Design: International adaptive platform; 2,274 critically ill patients

Intervention: Tocilizumab 8 mg/kg (max 800 mg) vs usual care

Key Results:

• Organ support-free days: 10 vs 0 (control)
• Hospital mortality: 28% vs 35.8% (adjusted OR 0.63)
• Synergistic with corticosteroids

Mechanism: IL-6 receptor antagonist; blocks cytokine storm-mediated tissue injury

Considerations: Screen for latent infections (TB, HBV); avoid if neutropenic/thrombocytopenic

Combined Use: Current recommendations - dexamethasone + tocilizumab for critically ill COVID-19. This combination represents immunomodulation at different levels of the inflammatory cascade."

---

Examiner: "How should ventilator allocation decisions be made if demand exceeds supply?"

Candidate: "Ventilator allocation during crisis standards requires both ethical framework and operational structure.

Ethical Principles:

1. Distributive justice: Allocate to maximize population benefit - prioritize those most likely to survive with intervention
2. Procedural justice: Transparent, consistent criteria applied to all; published framework; appeal mechanism
3. Non-discrimination: Allocation based on likelihood of benefit, NOT age alone, disability, socioeconomic status, Indigenous status
4. Separation of allocation from bedside care: Protect clinician-patient relationship

Triage Protocol (SOFA-Based):

• SOFA ≤7: High priority (most likely to benefit)
• SOFA 8-11: Intermediate priority
• SOFA ≥12: Low priority (unlikely to benefit regardless of intervention)
• Reassessment at 48-72 hours
• Increasing SOFA ≥3: Consider reallocation

Operational Structure:

Triage Committee:

• Senior intensivist NOT providing bedside care
• Senior nursing manager
• Ethics consultant
• Hospital administrator
• Aboriginal Health Worker/Liaison Officer for Indigenous patients

Process:

1. Bedside team identifies need for scarce resource
2. Committee reviews using objective criteria
3. Committee makes allocation decision
4. Bedside team implements and provides appropriate care
5. All decisions documented with rationale

Staff Protection:

• Removes moral burden from bedside clinician
• Consistent decisions across patients
• Appeal mechanism for contested cases
• Psychological support for committee members

Legal Protections:

• Crisis standards require formal governmental/institutional declaration
• Most Australian states provide liability protection for good faith decisions during declared emergencies
• Documentation essential for protection"

---

Examiner: "What considerations are specific to Aboriginal and Torres Strait Islander communities in pandemic response?"

Candidate: "Indigenous communities face unique vulnerabilities requiring specific pandemic response considerations.

Vulnerability Factors:

• Higher chronic disease prevalence: Diabetes 3x, cardiovascular disease 2x, CKD 3x general population
• Overcrowded housing: 15% vs 3% general population - increases transmission risk
• Remote community locations: Limited healthcare infrastructure, retrieval delays
• Historical trauma: Distrust of mainstream healthcare affecting engagement
• Language and health literacy barriers

Historical Impact:

• 1918-1919 Spanish Flu: 10x higher mortality in Indigenous communities
• 2009 H1N1: 4-5x higher hospitalization rates
• COVID-19: Early intervention protected communities; lower case rates due to prioritization

Culturally Appropriate Response:

Planning Phase:

• Engage ACCHOs as partners from outset
• Include Aboriginal Health Workers in planning teams
• Develop culturally appropriate communication materials
• Respect collective decision-making (extended family, Elders)

Response Phase:

• Aboriginal Hospital Liaison Officers in ICU for Indigenous patients
• Allow extended family involvement where possible
• Remote community protection: Biosecurity zones with community consent
• Priority vaccination (implemented successfully in COVID-19)
• Consider cultural practices in end-of-life care

ICU-Specific:

• AHLO notification on admission
• Family decision-making may involve Elders, extended family
• Interpreter services for language groups
• Cultural safety training for all staff
• Triage criteria must not discriminate against chronic disease burden

Māori Considerations (NZ):

• Te Tiriti o Waitangi: Partnership obligations
• Whānau-centered care
• Kaumātua (Elder) consultation
• Kaupapa Māori health services

These communities experienced historical trauma from pandemic response failures. Culturally appropriate engagement is both ethical obligation and practically essential for successful response."

---

Viva 2: Infection Prevention and Staff Wellbeing

Stem: "You are the ICU Director during a respiratory virus pandemic. Staff are expressing concerns about personal safety and visitation policies."

Duration: 12 minutes

---

Examiner: "Describe your approach to infection prevention for aerosol-generating procedures."

Candidate: "Infection prevention for AGPs requires understanding transmission dynamics, appropriate PPE, and environmental controls.

Definition and List of AGPs: AGPs generate respiratory aerosols capable of transmitting airborne pathogens. Key AGPs in ICU include:

• Intubation and extubation (highest risk)
• Non-invasive ventilation (NIV, BiPAP, CPAP)
• High-flow nasal oxygen (considered AGP in Australia/NZ)
• Bag-mask ventilation
• Open tracheal suctioning
• Bronchoscopy
• CPR (chest compressions with ventilation)
• Tracheostomy insertion and care

PPE Requirements for AGPs:

Standard AGP PPE:

• N95/P2 respirator (fit-tested within 12 months)
• Eye protection (goggles preferred; face shield acceptable)
• Long-sleeved fluid-resistant gown
• Gloves (double-gloving for high-risk procedures)

Enhanced PPE for Prolonged/High-Risk AGPs:

• PAPR for intubation, bronchoscopy, or staff with N95 fit difficulties
• Consider PAPR for any AGP >30 minutes

Environmental Controls:

• Negative pressure room (≥12 air changes/hour)
• If negative pressure unavailable: Portable HEPA filtration unit
• Minimize personnel in room during AGP
• Allow adequate air changes before non-N95 entry after AGP
• Enhanced surface cleaning post-procedure

Procedural Considerations:

Intubation:

• Most experienced operator (first-pass success)
• Video laryngoscopy (better visualization, maintains distance)
• Rapid sequence intubation (minimize bag-mask ventilation)
• Closed-circuit suction immediately after intubation

HFNO:

• Considered AGP in Australia (airborne precautions)
• Surgical mask over HFNO interface may reduce dispersion
• If precautions limiting availability, consider limiting flow rates or earlier intubation

Monitoring Compliance:

• Peer observation of donning/doffing
• Competency-based training with assessment
• Buddy system for complex PPE
• Reporting mechanism for breaches or concerns"

---

Examiner: "How would you address staff concerns about moral distress and burnout?"

Candidate: "Moral distress and burnout are significant issues during pandemic response, affecting 50-70% of ICU staff during COVID-19.

Understanding Moral Distress:

• Definition: Psychological distress when one knows the ethically appropriate action but is constrained from taking it
• Pandemic causes: Resource allocation decisions, inability to provide usual care, family visitation restrictions, isolated patient deaths, fear of infecting family

Prevention Strategies:

Ethical Framework:

• Clear, transparent triage protocols (reduces ambiguity)
• Triage committees make allocation decisions (removes burden from bedside staff)
• Published criteria known to all (consistent application)
• Appeal mechanisms (sense of fairness)

Leadership Communication:

• Transparent, frequent updates (twice daily during peak)
• Acknowledge uncertainty honestly
• Recognize challenges and contributions publicly
• Visible presence on clinical floor (leadership accessibility)

Resource Adequacy:

• Advocate for adequate PPE, staffing, equipment
• Transparent about resource status
• Explain rationale for conservation strategies

Immediate Support During Crisis:

Peer Support Programs:

• Trained peer supporters available on every shift
• Brief check-ins, psychological first aid
• Confidential, non-judgmental listening
• Referral pathway to professional support

Psychological First Aid Principles:

1. Safety: Ensure physical and psychological safety
2. Calming: Grounding, normalization of reactions
3. Self-efficacy: Promote sense of control
4. Connection: Team cohesion, social support
5. Hope: Realistic optimism, meaning-making

Practical Support:

• Rest areas with food, beverages, quiet space
• Accommodation for staff isolating from family
• Childcare assistance during extended hours
• Transportation support

Post-Pandemic Recovery:

Debriefing:

• Hot debrief: Immediately post-shift (practical focus)
• Cold debrief: Weeks-months later (emotional processing)
• Opt-in (not mandatory) individual and group sessions

Professional Support:

• Expanded EAP capacity
• Trauma-informed counseling
• CBT for persistent symptoms
• Medication if indicated (anxiety, depression, PTSD)

Long-Term Monitoring:

• Wellbeing check-ins at 6, 12, 24 months
• Monitoring for delayed-onset PTSD
• Return-to-work support
• Career counseling for those considering leaving

Evidence for Support Programs:

• Formal psychological support programs reduce burnout and turnover by 30-40%
• Peer support reduces moral distress scores
• Leadership communication is the strongest modifiable factor for staff wellbeing"

---

Examiner: "How would you manage family communication during visitor restrictions?"

Candidate: "Family communication during pandemic visitation restrictions is critical for family wellbeing and patient care. Restrictions increase family anxiety, prolonged grief, and PTSD.

Impact of Restrictions:

• Family PTSD rates: 30-50% during pandemic (higher than pre-pandemic)
• Complicated bereavement: Unable to be present at death
• Distrust: Families feel excluded from care decisions
• Isolation: Patients die alone, contrary to cultural practices

Alternative Communication Strategies:

Structured Communication:

• Daily scheduled phone calls (same time, consistent caller)
• Clear structure: Current status, changes, plan, opportunities for questions
• Allow time for emotional expression
• Document calls in medical record

Technology-Enabled Communication:

• Video calls: Tablet at bedside, facilitated by family liaison
• Virtual bedside visits: Scheduled "visiting hours" via video
• Photos: Daily photos sent to family showing patient (with consent)
• Milestone updates: Videos of extubation, progress, rehabilitation

Family Liaison Structure:

• Designated family liaison officer (one consistent contact)
• Single point of contact for family
• Coordinates with bedside team for updates
• Escalates concerns promptly
• Available for after-hours emergencies

Structured Meeting Protocol:

• Weekly family meetings (video if in-person restricted)
• Multidisciplinary (intensivist, nursing, social work, pastoral care)
• Goals of care discussions early
• Documentation with action plan

End-of-Life Considerations:

Preparing Families:

• Early discussion of prognosis and trajectory
• Prepare for possibility of rapid deterioration
• Discuss preferences for presence if death imminent

Facilitating Presence:

• Consider allowing one designated person for end-of-life
• Appropriate PPE provided and training given
• Virtual presence if physical not possible
• Staff presence at bedside if no family

Post-Death Support:

• Viewing with appropriate infection control
• Personal belongings returned with dignity
• Condolence call from treating team
• Bereavement follow-up (4-6 weeks)
• Information about grief support services

Cultural Considerations:

Indigenous Families:

• Extended family decision-making (more than immediate next-of-kin)
• Elder involvement in significant decisions
• Aboriginal Hospital Liaison Officer involvement
• Cultural practices at end-of-life (connection to Country, Sorry business)

Other Cultural Groups:

• Interpreter services for non-English speaking families
• Religious/spiritual support (chaplaincy)
• Respect for specific cultural death practices where possible
• Flexibility within infection control constraints

Documentation and Quality:

• Standardized communication log
• Family satisfaction surveys
• Complaint review and response
• Continuous improvement based on feedback"